OSLO, NORWAY--(Marketwired - April 17, 2013) - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces that members of its senior management and IR teams will participate in the following investor conference:
Kempen & Co. 6(th) Healthcare/Life Sciences Conference
Date: 23 April 2013
Participants:
Thomas Ramdahl (Chief Technology Officer)
Renate Birkeli (IR)
Venue: Amsterdam, The Netherlands
About Algeta
Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com.
Algeta to Participate in Upcoming Investor Conference:
http://hugin.info/134655/R/1693399/556601.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Algeta ASA via Thomson Reuters ONE
[HUG#1693399]
For further information, please contact:
Mike Booth / Renate Birkeli
+47 23 00 67 32
Communications & Corporate Affairs
Email Contact
Media enquiries:
Mark Swallow
+44 207 638 9571
Citigate Dewe Rogerson
Email Contact
Knut Ekern
+47 22 04 82 00
Gambit Hill & Knowlton
Email Contact
Kari Watson
+1 781 235 3060
MacDougall Biomedical Communications
Email Contact
US investor enquiries:
Tricia Swanson
+1 646 378 2953
The Trout Group
Email Contact
